Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6234 adjunct to incretin-based therapy in adults with obesity or overweight
2025-523295-23-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing AZD6234 + stable incretin-based therapy with Placebo + stable incretin-based therapy (2 arms). Primary endpoint: Percent change in body weight from baseline at 68 weeks of treatment. Planned start Oct 2026; status: authorised.
02
Drugs
lenbelintide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-523295-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523295-23-00.